Loading stock data…
Xeris Biopharma Holdings (XERS)
$8.48-0.05 (-0.59%)
Market ClosedLast close Sep 8
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Xeris Biopharma Holdings, Inc. in the Healthcare sector is trading at $8.48 with a market capitalization of $1.2B. Wall Street consensus targets $11.71 (7 analysts), implying a +38.1% move over the next 12 months. The stock is currently 16% below its 52-week high of $10.08, remaining 20.3% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +38.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 31) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $83.13M↓ | $85.81M↑ | $74.38M↑ | $71.54M↑ | $60.12M |
| Gross Profit | $72.55M↓ | $74.86M↑ | $63.38M↑ | $59.64M↑ | $51.39M |
| Operating Income | $7.92M↓ | $16.77M↑ | $6.73M↑ | $4.48M↑ | -$3.09M |
| Net Income | $2.23M↓ | $11.08M↑ | $621,000↑ | -$1.93M↑ | -$9.22M |
Peer Comparison
JNJUNHPFE
Fundamentals
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.18B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
92.29%
Volume
Today's trading volume
1.25M
Recent News
Why Xeris Biopharma Holdings (XERS) Is Up 8.4% After Tightening 2026 Revenue Guidance And Advancing XP-8121
Xeris Biopharma’s August 6, 2026 update showed second-quarter revenue rising to US$92.1 million while net loss widened to US$31.1 million, and the company tightened its full-year 2026 total revenue guidance to US$385 million–US$390 million. Alongside record quarterly revenue, Xeris highlighted strong Recorlev momentum, full retirement of its convertible notes, and progress toward a Phase III start for XP-8121, reshaping its operational profile. We’ll now examine how this tighter 2026 revenue...
Xeris Biopharma Holdings (XERS) Posts Record Q2 Revenue, Is It Still A Bargain?
Xeris Biopharma Holdings (XERS) is back in focus after reporting record second quarter revenue of $92.1 million and tightening its 2026 revenue outlook to a range of $385 million to $390 million. See our latest analysis for Xeris Biopharma Holdings. The latest record quarter and tighter 2026 revenue outlook have arrived after a strong run in Xeris Biopharma Holdings' stock, with a 33.49% 90 day share price return and a 292.92% three year total shareholder return, although the 1 day share...
Xeris (XERS) Q2 2026 Earnings Call Transcript
Recorlev revenue surged 81% year-over-year, driving tightened full-year guidance to $385M–$390M.
Xeris Biopharma Q2 Earnings Call Highlights
Xeris Biopharma (NASDAQ:XERS) reported second-quarter total revenue of $92.1 million, up 29% from a year earlier, as net product revenue increased 34% to $91 million. The company raised the low end of its full-year 2026 revenue outlook, now forecasting total revenue of $385 million to $390 million.
Xeris Biopharma Holdings Inc (XERS) (Q2 2026) Earnings Call Highlights: Record Revenue and ...
Xeris Biopharma Holdings Inc (XERS) posts a 29% revenue surge to $92.1 million, driven by RECORLEV's 81% growth, and lifts full-year 2026 outlook.